These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

312 related items for PubMed ID: 16797805

  • 1. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial.
    Gorse GJ, Keitel W, Keyserling H, Taylor DN, Lock M, Alves K, Kenner J, Deans L, Gurwith M.
    Vaccine; 2006 Aug 14; 24(33-34):5950-9. PubMed ID: 16797805
    [Abstract] [Full Text] [Related]

  • 2. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series.
    Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT.
    Vaccine; 2006 Apr 24; 24(17):3654-60. PubMed ID: 16497418
    [Abstract] [Full Text] [Related]

  • 3. Gorse GJ, et al. "Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial" [Vaccine 24 (2006) 5950-5959].
    Zink TK.
    Vaccine; 2007 Apr 12; 25(15):2766-7. PubMed ID: 17224206
    [Abstract] [Full Text] [Related]

  • 4. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M, Habermehl P, Faber J, Bock HL, Sänger R, Bogaerts H, Clemens R, Schuind A, du Prel JB, Schmitt HJ.
    Vaccine; 2006 Jul 07; 24(27-28):5627-36. PubMed ID: 16740348
    [Abstract] [Full Text] [Related]

  • 5. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
    Rynkiewicz D, Rathkopf M, Sim I, Waytes AT, Hopkins RJ, Giri L, DeMuria D, Ransom J, Quinn J, Nabors GS, Nielsen CJ.
    Vaccine; 2011 Aug 26; 29(37):6313-20. PubMed ID: 21624418
    [Abstract] [Full Text] [Related]

  • 6. Results of a safety and immunogenicity study of an early-stage investigational rPA102 vaccine as compared to the FDA licensed anthrax vaccine (anthrax vaccine adsorbed (AVA. BioThrax)).
    Hannesschlager JR.
    Vaccine; 2007 Apr 30; 25(17):3247. PubMed ID: 17234308
    [No Abstract] [Full Text] [Related]

  • 7. Comparability of ELISA and toxin neutralization to measure immunogenicity of Protective Antigen in mice, as part of a potency test for anthrax vaccines.
    Parreiras PM, Sirota LA, Wagner LD, Menzies SL, Arciniega JL.
    Vaccine; 2009 Jul 16; 27(33):4537-42. PubMed ID: 19501205
    [Abstract] [Full Text] [Related]

  • 8. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine.
    Lininger LA, Cullum ME, Lyles MB, Bienek DR.
    Vaccine; 2007 Feb 19; 25(9):1619-25. PubMed ID: 17150286
    [Abstract] [Full Text] [Related]

  • 9. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.
    Little SF, Ivins BE, Webster WM, Norris SL, Andrews GP.
    Vaccine; 2007 Apr 12; 25(15):2771-7. PubMed ID: 17240008
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of a novel recombinant protective antigen anthrax vaccine (GC1109), a randomized, single-blind, placebo controlled phase II clinical study.
    Kang CK, Kim NH, Kim CJ, Rhie GE, Jo SK, Ahn M, Kang J, Choe PG, Park WB, Kim NJ, Oh MD.
    Vaccine; 2019 Jun 27; 37(29):3820-3824. PubMed ID: 31151800
    [Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of oral killed whole cell recombinant B subunit cholera vaccine in Barranquilla, Colombia.
    Concha A, Giraldo A, Castañeda E, Martínez M, de la Hoz F, Rivas F, Depetris A, Svennerholm AM, Sack DA.
    Bull Pan Am Health Organ; 1995 Dec 27; 29(4):312-21. PubMed ID: 8605522
    [Abstract] [Full Text] [Related]

  • 12. Effect of delayed anthrax vaccine dose on Bacillus anthracis protective antigen IgG response and lethal toxin neutralization activity.
    Pittman PR, Fisher D, Quinn X, Schmader T, Barrera-Oro JG.
    Vaccine; 2013 Oct 17; 31(44):5009-14. PubMed ID: 24026013
    [Abstract] [Full Text] [Related]

  • 13. Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.
    Bellanti JA, Lin FY, Chu C, Shiloach J, Leppla SH, Benavides GA, Karpas A, Moayeri M, Guo C, Robbins JB, Schneerson R.
    Clin Vaccine Immunol; 2012 Feb 17; 19(2):140-5. PubMed ID: 22190398
    [Abstract] [Full Text] [Related]

  • 14. Analysis of anti-protective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax.
    Semenova VA, Schmidt DS, Taylor TH, Li H, Steward-Clark E, Soroka SD, Ballard MM, Quinn CP.
    Vaccine; 2007 Feb 26; 25(10):1780-8. PubMed ID: 17229495
    [Abstract] [Full Text] [Related]

  • 15. Reproductive toxicity of BioThrax in rabbits.
    Franco C, Lewis E, Morseth S, Simon L, Waytes AT.
    Birth Defects Res B Dev Reprod Toxicol; 2009 Oct 26; 86(5):370-6. PubMed ID: 19718687
    [Abstract] [Full Text] [Related]

  • 16. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine.
    Grunow R, Porsch-Ozcürümez M, Splettstoesser W, Buckendahl A, Hahn U, Beyer W, Böhm R, Huber M, vd Esche U, Bessler W, Frangoulidis D, Finke EJ.
    Vaccine; 2007 May 04; 25(18):3679-83. PubMed ID: 17287051
    [Abstract] [Full Text] [Related]

  • 17. Ability of ELISA and a toxin neutralization assay to detect changes in immunogenicity of a recombinant Bacillus anthracis protective antigen vaccine upon storage.
    Domínguez-Castillo RI, Verma A, Amador-Molina JC, Sirota L, Arciniega JL.
    Biologicals; 2013 Mar 04; 41(2):111-4. PubMed ID: 23137818
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.
    Krishnan V, Andersen BH, Shoemaker C, Sivko GS, Tordoff KP, Stark GV, Zhang J, Feng T, Duchars M, Roberts MS.
    Clin Vaccine Immunol; 2015 Apr 04; 22(4):430-9. PubMed ID: 25673303
    [Abstract] [Full Text] [Related]

  • 19. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, Stenz JP, Cheff A, Richardson C.
    Vaccine; 2006 May 01; 24(18):3953-63. PubMed ID: 16530302
    [Abstract] [Full Text] [Related]

  • 20. Duration of protection of rabbits after vaccination with Bacillus anthracis recombinant protective antigen vaccine.
    Little SF, Ivins BE, Webster WM, Fellows PF, Pitt ML, Norris SL, Andrews GP.
    Vaccine; 2006 Mar 24; 24(14):2530-6. PubMed ID: 16417950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.